MediciGlobal

Patients ‘lost’ from a clinical trial result in study delays, increased patient recruitment costs and compromised study data. The company, L2FU provides critical solutions.

Pivotal clinical trials must be properly powered based upon the level of activity shown in earlier trials and preclinical studies. Big Pharma typically power their trials at no less than 80 percent. Emerging biotechs designing pivotal trials for their one drug candidate often aim to power the trials at 90 percent.

But when patients are lost to follow up, it can result in the ‘tombstone’ press release stating that “while the data from the trial showed ‘positive trends’, the results were not statistically significant and the endpoints were not met.” Lost to follow up (L2FU) rates in clinical research trials can range from 20- 60%.

There is a positive trend however, companies are becoming more proactive in implementing patient retention programs and implementing a more proactive approach to lost-to follow up management to find or reconnect with lost study subjects. These approaches are yielding excellent outcomes.

The L2FU team helps clinical trial sites and biopharma companies to locate contact and collect data from patients deemed ‘Lost to Follow-Up’. The L2FU team provides clinical trial sponsors the reassurance that missing patients and required outcome data will be accounted for. Employing the specialty company L2FU to locate and reconnect with lost patients, allows already overworked study coordinators to focus their time on active patients in the study.

L2FU is building a portfolio of successes and an industry reputation for its quality work.

This week, the L2FU team proudly reported its latest successful recovery of 100% of a recent study’s lost clinical trial patients. This was achieved in only one month to meet a truncated timeline. The client, a leading integrated managed care organization, with operations in a number of major states across the US and nearly 10 million patient members, required the information rapidly.

L2FU is part of MediciGlobal, a global leader in the recruitment and retention of patients for clinical trials. With more than 20 years of clinical trials experience in patient recruitment-retention, MediciGlobal is a company dedicated to the recruitment-retention and reconnection of patients for clinical trials. For more information on L2FU visit http://www.L2FU.com or call Bernard Hall at 484-674-6816.